新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » 生物产业蓬勃发展,风投云集波士顿、旧金山

生物产业蓬勃发展,风投云集波士顿、旧金山

来源:生物谷 2015-02-14 14:56

2015年2月14日讯 /生物谷BIOON/ --近年来生命科学产业的飞速发展吸引了众多投资者的目光。2014年刚过,来自PricewaterhouseCoopers公司和美国风险投资协会的分析师们对去年投放在生命科学领域的资金进行了评估。结果发现,2014年进入该领域的风险投资金额已经达到了86亿美元,仅次于2007年。其中在生物技术产业领域投资金额达到了60亿美元,比2013年飙升了29%之多。以2014年第四季度为例,风投公司向生命科学公司投入的首次投资金额就超过了4亿美元,比去年同时期增加了35%;而追加投资则达到了24亿美元,增长了超过50%之多。据统计数据显示,2014年生命科学领域全年吸收的首次投资额达到了11亿美元,上涨了25%;追加操作达到了75亿美元,上涨了29%。可以说,2014年生物医药产业已经成为了最受投资者青睐的行业之一。

而作为美国传统的生命科学中心,旧金山湾区和波士顿都吸引了数目巨大的风投资金。同样以第四季度为例,波士顿在这三个月中达成了32项投资案,资金总额达到了9亿5千9百万美元。其中9亿2千8百万美元的资金流入生物技术类公司,剩余的3100万美元则用于支持医疗器械类公司的发展。而旧金山湾区则以8亿3千9百万美元的成绩屈居榜眼。

来自PricewaterhouseCoopers公司的Greg Vlahos介绍说,风投公司在2014年第二季度开始加大向生命科学产业的投资,而这一增长趋势一致持续到了2014年第四季度,因此我们有理由认为2015年生物医药产业仍将吸引更多的风投资金。此外,在传统的生物医药公司外,医疗器械研发商也获得了众多风险投资公司的青睐。这些资金将有助于加快生物医药行业的整体发展。(生物谷Bioon.com)

详细英文报道:

The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the numbers for 2014. And the boom in venture investing looks set to continue well into 2015, according to the analysts at PricewaterhouseCoopers and the National Venture Capital Association, working with data provided by Thomson Reuters to put out the MoneyTree report.

2014 fell just short of 2007 with $8.6 billion invested in the entire life sciences sector (combining biotech and med tech). Biotech venture funding alone jumped to $6 billion, a 29% spike over a healthy 2013, when the industry boom was beginning to take shape as the IPO window finally cranked all the way open after a long fallow period.

Zeroing in on just the fourth quarter, venture groups put $403 million into first-time funding for life sciences companies, an increase of 35%. But the year offered a bonanza at just about every level, with follow-on funding soaring 51% to $2.4 billion in the fourth quarter. For the full year first-time funding hit $1.1 billion, up 25%, while follow-on funding rose 29% to $7.5 billion.

While San Francisco has often outranked Boston in terms of quarterly biotech investing, there was no mistaking where the bulk of the cash headed in the final three months of the year.

Boston topped all the big life science clusters, with $959 million in 32 deals during the quarter; $928 million going into biotechnology and the remaining $31 million invested in medical devices. The San Francisco Bay Area came in as a close runner-up, capturing $839 million. The Big Apple came in a surprising third place, with $175 million, while Research Triangle gained $127 million and Chicago made the cut with $90 million invested. Equally surprisingly, San Diego didn't land a spot in the top 5.

"The life sciences sector saw five megadeals last year, a testament to the highly innovative biotech and medical device technologies and the resulting confidence of venture capitalists in the business models of these start-ups," said Greg Vlahos, life sciences partner at PwC, in a statement. "The biotechnology industry attracted record-high venture investments in the second quarter of 2014 and ended the year with even higher investments in the fourth quarter. In addition, the medical device industry continued to show strong growth for the year. This is in line with PwC's projection in early 2014 of a very strong year for life sciences. Given the strong level of investments in this sector and others in recent quarters, we expect continued high investment levels in life sciences in the first half of 2015."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库